SCHEMBL6522754

SCHEMBL6522754

CC(C)(O)c1cccc(-c2ccc3nc(-c4ccc5c(c4)CCO5)cn3c2)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 6/20 0.63
KCNH2 Q12809 2/20 0.63
KDM4E B2RXH2 5/20 0.48
NPC1 O15118 5/20 0.48
MAPT P10636 4/20 0.48
RAB9A P51151 4/20 0.48
PKM P14618 2/20 0.48
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ALDH1A3 P47895 5/20 0.40
CYP2C9 P11712 1/20 0.40
ALDH1A2 O94788 1/20 0.40
DYRK1A Q13627 2/20 0.40
SLC2A1 P11166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430260 0.82 NR4A2 (0.62) NR4A2KCNH2KDM4ENPC1MAPT
SCHEMBL3429522 0.79 NR4A2 (0.69) NR4A2KCNH2NPC1RAB9APKM
SCHEMBL1472110 0.78 NR4A2 (1.00) NR4A2KCNH2KDM4ENPC1RAB9A
SCHEMBL3431737 0.78 NR4A2 (0.75) NR4A2KCNH2ALDH1A1CYP11B1CYP11B2
SCHEMBL3429517 0.78 NR4A2 (0.68) NR4A2KCNH2ALDH1A1CYP11B1CYP11B2
SCHEMBL3430915 0.78 NR4A2 (0.68) NR4A2KCNH2NPC1RAB9AALDH1A1
SCHEMBL3431035 0.76 NR4A2 (0.68) NR4A2KCNH2NPC1ALDH1A1CYP11B1
SCHEMBL3433239 0.75 ADORA2A (0.62) KDM4ENPC1MAPTRAB9APKM
SCHEMBL3432610 0.75 NR4A2 (0.67) NR4A2KCNH2NPC1MAPTRAB9A
SCHEMBL3432413 0.75 NR4A2 (0.71) NR4A2KCNH2ALDH1A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP claimed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US claimed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885KCNH2 1938/4885KDM4E 1761/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885KCNH2 1938/4885KDM4E 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.